Piper Jaffray
Piper Jaffray is a client-focused, middle market investment bank and institutional securities firm founded in 1895 and based in Minneapolis, Minnesota.
Its Investment Banking activities include raising capital through equity and debt financings for corporate clients; providing financial advisory services relating to mergers and acquisitions to consumer, financial institutions, health care, technology, alternative energy, business services, and industrial growth sectors; underwriting debt issuances for government and non-profit clients; and providing financial advisory and interest rate risk management services.
The company's equity and fixed income institutional sales and trading activities include equity and fixed income advisory and trade execution services for public and private corporations, public entities, non-profit clients, and institutional investors.
-
Notable Analyst Rating Changes 06/22: VRX, LNCR, MAT, ARBA Upgraded; BVF, BIG, WAG, NOV Downgraded
-
Piper Jaffray Downgrades Biovail (BVF) to Neutral Following Merger Announcement
-
Piper Jaffray Upgrades Valeant Pharmaceuticals (VRX) to Overweight; Compelling Cash Flow Story with Addition of BVF
-
Unusual 11 Mid-Day Movers 06/21: EFJI, AIPC, UTSI, MELA, RADA, BVF Higher; AFFY, CYPB, ZIOP, FORD, PCBC Lower
-
Morning Movers 6/21: EFJI, AIPC, GKK, RADA, BVF Higher; AFFY, ZIOP, UAHC, CYPB, CPKI Lower
-
Shares of Valeant Pharmaceuticals (VRX) Up Over 20% in Past Six Sessions
-
Piper Jaffray Upgrades Valeant Pharmaceuticals (VRX) to Neutral; Hard to Argue with this Kind of Execution
-
Piper Jaffray Initiates Coverage on Valeant Pharmaceuticals (VRX) with an Underweight; Valuation Based on Sum-of-the-Parts
